If this message is not displayed correctly, click here.

No 91, November 2016


Are you an ERA-EDTA Member? Register to ENP and discover the exclusive content!

Are you an ERA-EDTA member but have not yet registered to ENP? Do it now and access all the educational content available for ERA-EDTA Members only: CME Course slides, selected materials of National and International Societies, 2016 Congress presentations and posters (unlimited access to Congress delegates who are also member of the ERA-EDTA)! Many educational tools will be available in the near future!
Click on ‘Sign up‘ and register here!


Register NOW for the NEW European Nephrology Examination

3 years’ FREE membership of the ERA-EDTA is offered to the first 100 candidates who register, provided they are either below 40 years old or from a lower income country.
Registrations are open until December 7, 2016. For more information and to register click here.

Just published online! Read the latest NDT and CKJ articles

Just published online! Read the latest NDT and CKJ articles

How safe and efficient is sofosbuvir in HCV-infected CKD patients?
The aim of this multicentre retrospective study was to assess the antiviral efficacy and safety of sofosbuvir in HCV-infected patients with severe renal failure. 50 patients – among them were 35 hemodialysis patients – received a sofosbuvir based combination therapy for 12 or 24 weeks. HD patients were treated with a reduced dose of sofosbuvir (400 mg three times a week or 400 mg every other day). With a response rate of 86% at week 12 the medication proved to be efficient. Besides, no patient had to discontinue the treatment due to side effects.

Read More →

Treating MN patients with rituximab was efficient and remarkably safe
In this study, which has recently been published in NDT, 38 patients with idiopathic membranous nephropathy (MN) were treated with retuximab over a period of 15 months. 29 of the patients achieved a partial or complete remission. Besides, proteinuria was reduced significantly and renal function could be stabilized. No significant adverse events were described – therefore the authors concluded that the therapy was “remarkably safe”.

Read More →

Abstract Submission online is open now!

Do not miss the opportunity to submit your work to the ERA-EDTA Congress in Madrid (3-6 June, 2017) and be part of the exciting scientific program which will be presented. The abstract submission will be open until 27 January, 2017!
In order to submit your work, please visit the Abstract webpage.

ERA-EDTA Flash is the official ERA-EDTA eNewsletter

Editor-in-Chief: Mustafa Arici
Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini

ERA-EDTA Headquarters
Via XXIV Maggio, 38
43123 Parma - Italy

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003. If at any time you wish to change personal information that is incorrect or wish to have your personal data deleted, please REPLY this email and specify ‘REMOVE ME FROM YOUR DATABASE’. ERA-EDTA will meet such requests at the earliest possible opportunity by deleting or amending your personal information.